Latest KFF Health News Stories
KHN’s ‘What the Health?’: Washington’s Slow Churn
Stemming gun violence is back on the legislative agenda following three mass shootings in less than a month, but it’s hard to predict success when so many previous efforts have failed. Meanwhile, lawmakers must soon decide if they will extend current premium subsidies for those buying health insurance under the Affordable Care Act, and the Biden administration acts, belatedly, on Medicare premiums. Margot Sanger-Katz of the New York Times, Sandhya Raman of CQ Roll Call, and Rachel Cohrs of Stat News join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Michelle Andrews, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a too-common problem: denial of no-cost preventive care for a colonoscopy under the Affordable Care Act.
Medicare Surprise: Drug Plan Prices Touted During Open Enrollment Can Rise Within a Month
Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications is no bargain after prices go up.
Journalists Cover the Gamut, From Rising Insulin Costs to Delays in Autism Care for Children
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
US Rep. Gaetz’s Diagnosis of What’s Driving Insulin Costs Misses the Root Cause
A diabetes diagnosis is not always related to a person’s weight or overall health, especially for those with Type 1 diabetes, who are dependent on insulin treatment for life.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
KHN’s ‘What the Health?’: News You Might Have Missed
Congress is in recess, so the slower-than-average news week gives us a chance to catch up on underreported topics, like Medicare’s coverage decision for the controversial Alzheimer’s disease drug Aduhelm and ominous new statistics on drug overdose deaths and sexually transmitted diseases. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
KHN’s ‘What the Health?’: Finally, a Fix for the ‘Family Glitch’
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
A KFF Health News database tracks campaign donations from drugmakers over the past 10 years.
California Governor’s Big Promises on Drug Prices Are Slow to Materialize
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven’t been as monumental as he promised. And his plan to have California make its own generic drugs hasn’t gotten off the ground.
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
I Write About America’s Absurd Health Care System. Then I Got Caught Up in It.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: The Big Biden Budget Bill Passes the House
President Joe Biden’s social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week’s Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
Cómo las comunidades rurales están perdiendo sus farmacias
Las farmacias de las esquinas, que alguna vez estuvieron tanto en las grandes ciudades como en los pueblos rurales, están desapareciendo de muchas áreas del país, dejando a unos 41 millones de estadounidenses en lo que se conoce como “desiertos de farmacias”, sin fácil acceso a las farmacias.
How Rural Communities Are Losing Their Pharmacies
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
Hormone Blocker Sticker Shock — Again — As Patients Lose Cheaper Drug Option
Kids who need a hormone-blocking drug to delay puberty have lost an off-label option. The nearly identical drug the company still sells costs eight times more.
